Effects of varied doses of psilocybin on time interval reproduction in human subjects
This double-blind, placebo-controlled, within-subjects study (n=21) investigated the effects of psilocybin (0.84, 8.05, & 17.5mg/70kg) on time perception and found that it increased the loss rate of internal time representation even within the microdose range. This may indicate psilocybin's subjective effects, such as the experience of ‘time standing still'.
Authors
- Franz Vollenweider
- Felix Hasler
Published
Abstract
Introduction
Awareness of temporal order of events and the ability to discriminate temporal durations are typical for the normal, wakeful conscious state, whereas alterations of subjective time experience are often observed in so-called ‘altered states of consciousness’ (ASC).
Methods
Action of a hallucinogenic substance, psilocybin, on internal time representation was investigated in two double-blind, placebo-controlled studies: Experiment 1 with 12 subjects and graded doses, and Experiment 2 with 9 subjects and a very low dose. The task consisted in repeated reproductions of time intervals in the range from 1.5 to 5 s. The effects were assessed by parameter κ of the ‘dual klepsydra’ model of internal time representation, fitted to individual response data and intra-individually normalized with respect to initial values.
Results
The estimates κˆ were in the same order of magnitude as in earlier studies. In both experiments, κ was significantly increased by psilocybin at 90 min from the drug intake, indicating a higher loss rate of the internal duration representation.
Discussion
These findings are tentatively linked to qualitative alterations of subjective time in altered states of consciousness.
Research Summary of 'Effects of varied doses of psilocybin on time interval reproduction in human subjects'
Introduction
Awareness of temporal order and the ability to discriminate durations are features of normal wakeful consciousness, while altered states of consciousness (ASC) commonly produce changes in subjective time experience. Earlier research has reported that psilocybin, a serotonergic hallucinogen acting primarily at 5-HT2A/1A receptors, produces subjective and objective alterations in time perception: shortened reproductions of intervals longer than about 2.5 s, impaired synchronization to slower inter-beat intervals, slowed preferred tapping rates, working-memory deficits, and reported disturbances in subjective time sense. These findings align with evidence that serotonergic modulation of prefrontal cortex—an area implicated in timing behaviour—can alter timing performance. This study applies a parametric modelling approach to duration-reproduction data, using the dual klepsydra model (DKM) of internal time representation. Rather than analysing reproduction errors separately for each stimulus duration, the investigators fit the DKM to whole-response functions and focused on its single key parameter κ, the loss-rate coefficient of the model's leaky accumulators. The paper reports two double-blind, placebo-controlled experiments aimed at testing whether psilocybin alters κ during the peak drug effect and thereby affects the internal representation of supra-second time intervals.
Expert Research Summaries
Go Pro to access AI-powered section-by-section summaries, editorial takes, and the full research toolkit.
Full Text PDF
Full Paper PDF
Create a free account to open full-text PDFs.
Study Details
- Study Typeindividual
- Journal
- Compound
- Topic
- Authors
- APA Citation
Wackermann, J., Wittmann, M., Hasler, F., & Vollenweider, F. X. (2008). Effects of varied doses of psilocybin on time interval reproduction in human subjects. Neuroscience Letters, 435(1), 51-55. https://doi.org/10.1016/j.neulet.2008.02.006
References (4)
Papers cited by this study that are also in Blossom
Carter, O., Burr, D. C., Pettigrew, J. D. et al. · Journal of Cognitive Neuroscience (2006)
Hasler, F., Grimberg, U., Benz, M. A. et al. · Psychopharmacology (2004)
Vollenweider, F. X., Vollenweider-Scherpenhuyzen, M. F. I., Bäbler, A. et al. · NeuroReport (1998)
Wittmann, M., Carter, O., Hasler, F. et al. · Journal of Psychopharmacology (2007)
Cited By (23)
Papers in Blossom that reference this study
Scholle, P., Wenke, Š., Nekovářová, T. et al. · Journal of Psychopharmacology (2026)
Nayak, S., Bradley, M. K., Kleykamp, B. A. et al. · Journal of Clinical Psychiatry (2023)
Glowacki, D. R., Wonnacott, M. D., Freire, R. et al. · Scientific Reports (2022)
McCulloch, D. E-W., Madsen, M. K., Jensen, P. S. et al. · Frontiers in Pharmacology (2022)
Villiger, D. · Frontiers in Psychiatry (2022)
Sekula, A. D., Downey, L., Puspanathan, P. · Frontiers in Psychology (2022)
Polito, V., Liknaitzky, P. · Psyarxiv (2021)
Ballentine, G., Friedman, S. F., Bzdok, D. · Science Advances (2021)
Barrett, F. S., Krimmel, S. R., Griffiths, R. R. et al. · NeuroImage (2020)
Bornemann, J. · Journal of Psychoactive Drugs (2020)
Show all 23 papersShow fewer
Carhart-Harris, R. L., Friston, K. J. · Pharmacological Reviews (2019)
Bayne, T., Carter, O. · Neuroscience of Consciousness (2018)
Swanson, L. R. · Frontiers in Pharmacology (2018)
Kaelen, M. · Imperial College London (2017)
Preller, K. H., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Nichols, D. E. · Pharmacological Reviews (2016)
McKenna, D., Riba, J. · Current Topics in Behavioral Neurosciences (2016)
Kometer, M., Vollenweider, F. X. · Behavioral Neurobiology of Psychedelic Drugs (2016)
Nutt, D. J., Carhart-Harris, R. L. · Current Drug Abuse Reviews (2015)
Bouso, J. C., Fábregas, J. M., Antonijoan, R. M. et al. · Psychopharmacology (2013)
Bogenschutz, M. P. · Current Drug Abuse Reviews (2013)
Studerus, E., Kometer, M., Hasler, F. et al. · Journal of Psychopharmacology (2010)
Carhart-Harris, R. L., Friston, K. J. · Brain (2010)
Your Personal Research Library
Go Pro to save papers, add notes, rate studies, and organize your research into custom shelves.